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Summary Hyperresponsiveness (AHR) is a key physiological abnormality in asthma.
In clinical and research studies AHR is measured bronchial challenge, with
methacholine (MCh), but more recently with adenosine-50-monophosphate (AMP).
In the search for markers of airway inflammation in asthmatic patients, we
measured the concentrations of histamine and cysteinyl-leukotrienes (cys-LTs)
before and after MCh and AMP challenges in the exhaled breath condensate of 13
patients with mild asthma (FEV1 78.5%pred) and nine healthy non-smokers, using
specific enzyme immunoassays.
With methacholine challenge we did not find any differences between asthmatics
and normal subjects in the pre- and post-challenge concentrations of cys-LTs:
27.271.4 vs. 29.271.2 pg/ml and 26.372.2 vs. 27.574.2 pg/ml, respectively or
histamine: 5.170.4 vs. 5.170.6 nM and 4.570.4 vs. 4.470.3 nM; P40.05). In
asthmatic patients cys-LT levels were significantly higher after AMP challenge
(56.279.7 vs. 31.776.9 pg/ml; Po0.05); but there was no difference in healthy
subjects (27.274.6 vs. 30.374.7 pg/ml). There was no difference in histamine
concentrations in asthmatic (5.971.8 vs. 4.570.5 nM), or healthy subjects (5.570.4
vs.5.770.9 nM) after AMP challenge.
In conclusion, our results show that the cys-LTs are increased in exhaled breath
condensate after AMP challenge, which may indicate that the AMP acts indirectly by
releasing cys-LTs from primed mast cells. The detection of LTs and histamine in
exhaled breath condensate may be useful in monitoring asthma.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is an inflammatory disease of the airways
associated with airway hyperresponsiveness (AHR)
and variable airflow obstruction. The demonstra-
tion of AHR is widely advocated as a useful
diagnostic test in the evaluation of possible asth-
matics. AHR can be defined as an increased
tendency of the airways to constrict excessively
under the influence of various stimuli.1 In clinical
and research studies, AHR is measured by means of
a bronchial challenge, usually with methacholine,
histamine or adenosine-50-monophosphate (AMP).
Methacholine (MCh) and histamine act directly on
airway smooth muscle, whereas AMP acts indirectly
by causing primed mast cell degranulation and the
release of proinflammatory mediators, such as
histamine and leukotrienes.2
The inflammatory process in asthma involves
multiple mediators, of which histamine was one of
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the first to be discovered; it is synthesised and
released by mast cells in the airway wall and by
circulating and infiltrating basophils. Recent evi-
dence relating to the biochemistry, pathophysiol-
ogy and antagonism of cysteinyl-leukotrienes (cys-
LTs) suggests that they play a role in the pathophy-
siology of asthma.3 Cys-LTs are produced predomi-
nantly by mast cells and eosinophils, large numbers
of which are present in or recruited to the airways
of asthmatic patients.
Airway inflammation can also be monitored by
measuring non-invasive and sensitive markers, such
as induced sputum 4 and exhaled nitric oxide (NO),5
which may provide additional information for
assessing asthma control. Exhaled breath conden-
sate has also recently been used to assess inflam-
matory molecules derived from the respiratory
tract, which it may contain. It is assumed that
the airway surface liquid becomes aerosolised
during turbulent airflow, and so the content of
the condensate reflects the composition of airway
surface liquid.6
The aim of this study was to investigate whether
histamine and cys-LTs can be detected in the breath
condensate of asthmatic patients and healthy
controls before and after bronchoconstriction
induced by MCh and AMP challenge. AMP is in
asthma patients bronchoconstrictor and is assumed
to cause bronchoconstriction indirectly by releasing
bronchoconstrictor mediators, such as histamine or
cys-LTs from mast cells.2
Methods
Study subjects
The study included 13 non-smoking asthma patients
aged 24.472.6 years, and nine healthy controls
without signs or symptoms of upper or lower
respiratory disease. All patients had mild episodic
asthma with forced expiratory volume in 1 s (FEV1)
of 8371.4% of predicted value and a bronchodi-
lator response to 200 mg of Salbutamol (FEV1
increase 4200ml or 12% of baseline value). Their
asthma was clinically stable and there had been no
worsening in symptoms during the previous 8 weeks
(Table 1).
The patients used only short-acting inhaled B-
agonists to control their asthma during the 2 weeks
before screening and no patient was taking inhaled
corticosteroids. The study was approved by the
Ethics Committee of the Royal Brompton Hospital
and Harefield NHS Trust, and informed consent was
obtained from all the patients.
Study design
The patients were asked to visit the hospital on two
occasions separated by an interval of at least 48 h
in order to undergo MCh and AMP challenges in
random order. The challenges were carried out
after the baseline measurement of FEV1 and the
collection of exhaled condensate for 10min, which
was repeated immediately after the challenges.
Pulmonary function
Pulmonary function was measured using a dry
spirometer (Vitalograph Ltd, Buckingham, UK);
the mean of the three manoeuvres was expressed
as an absolute value (in litres) and a percentage of
the predicted value.
Inhalation challenge tests
Before the MCh and AMP challenges, the patients
were instructed to withhold medications for the
following time intervals: salbutamol for 6 h, oral
antihistamines for 48 h, nasal sodium cromoglycate
for 24 h, and intranasal anticholinergics and topical
nasal decongestants for 48 h. They also had to avoid
exercise or cold air exposure for at least 2 h and
refrain from the ingestion of coffee, tea, cola and
chocolate for at least 6 h before the challenge.
Methacholine chloride and AMP (Sigma Chemical
Co., Poole, UK) were dissolved in 0.9% sodium
chloride to produce a range of doubling concentra-
tions (from 0.06 to 64mg/ml for MCh and from
0.048 to 400mg/ml for AMP) and then used
immediately for bronchial challenge.
The doses were inhaled through a nebulizer
attached to a breath-activated dosimeter (Mefar,
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Table 1 Physical characteristics and pulmonary
function of subjects.
Parameters Asthmatics Healthy
Number 13 9
Age (yr) 24.472.6 33.279.6
Sex (F/M) 8/5 5/4
FEV1 (L) 2.670.8 3.670.6
FEV1 (% pred.) 8371.4 97712.3
FVC (L) 3.4070.5 3.3570.9
FVC (% pred.) 94.372.6 9770.07
PC20 (MCh) mg/ml 4.571.7 450
PC20 (AMP) mg/ml 12.272 4100
FEV1¼ forced expiratory volume in 1 s; FVC¼ forced vital
capacity. PC20¼Mean values7SEM.
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Brescia, Italy). A standard procedure was used for
all of the provocation tests. Three values of FEV1
were recorded at 1min intervals and the highest
value was taken as baseline. Subjects inhaled five
1-s breaths of normal saline as a control and held
their breath for 6 s, FEV1 was measured 2min later.
They then inhaled a series of doubling concentra-
tions of MCh or AMP (starting with the lowest dose)
at 3-min intervals and FEV1 was measured 2min
after each dose. The challenges were stopped when
FEV1 fell by420% from the post-saline value or the
top dose was reached. A long dose–response curve
was constructed and the concentration causing a
20% drop in FEV1 from the post-saline value (PC20)
was calculated by means of linear interpolation and
expressed in cumulative units.
Exhaled breath condensate
Exhaled breath condensate was collected immedi-
ately following the spirometry and after the last
dose of bronchoconstrictor. The breath condensate
samples were collected using a specially designed
condensing chamber (Ecoscreen; Jaeger, Hoech-
berg, Germany); exhaled air enters and leaves the
chamber through one-way inlet and outlet valves,
thus keeping the chamber closed. The subjects
wore nose clips and breathed tidally through a
mouthpiece connected to the condenser for 10min
as previously described.7 Approximately 1ml of
condensate was stored at 701C in a 2-ml sterile
plastic tube.
Histamine and cys-LT assays
Histamine and cys-LT concentrations in the breath
condensate were measured using specific enzyme
immunoassay (EIA) kits (Cayman Chemical, Ann
Arbor, USA). The assays were validated directly, by
means of gas chromatography/mass spectrometry
in order to obtain a close correlation (r¼ 0.95)
between known amounts of histamine and cys-LTs
and the concentrations measured by the EIA. The
detection limit of the assay was 13 pg/ml for cys-LTs
and 0.5 nM for histamine after a 2-h development
period.
Statistical analysis
The data were expressed as mean values 7
standard deviations, with significance being de-
fined as a P value of o0.05. The intra-group
differences were compared using Student’s t-test
for paired data and the differences between groups
were compared using the Mann–Whitney U-test.
The relationships between the clinical data and
histamine and cys-LT concentrations in the breath
condensates were investigated by means of Spear-
man’s correlation.
Results
Methacholine challenge
There was no difference between asthmatic and
healthy control subjects at baseline in histamine
(5.170.4 vs. 4.570.4 nM; P40.05) or cys-LTs
concentrations (27.271.4 vs. 26.372.2 pg;
P40.05) in exhaled breath condensate.
Histamine was detectable in breath condensates
of all asthmatic patients and control subjects, and
its concentrations were unchanged after MCh
challenge (5.170.6 vs. 4.470.3 nM; P40.05, asth-
matics and healthy, respectively, Fig. 1). Cys-LTs
were detectable in 11/13 patients and in all
healthy and similarly no difference was found after
the challenge (29.271.2 vs. 27.574.2 pg/ml;
P40.05, Fig. 2).
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Figure 1 Exhaled breath concentrations of histamine in
healthy control (Panel A) and patients with asthma (Panel
B) after methacholine challenge.
Figure 2 Exhaled breath concentrations of cys-LT in
healthy control (Panel A) and patients with asthma (Panel
B) after methacholine challenge.
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AMP challenge
There was no difference between asthmatic and
healthy control subjects at baseline in histamine
(5.971.4 vs. 5.570.4 nM; P40.05) or cys-LTs
concentrations (31.776.9 vs. 27.274.6 pg;
P40.05) in exhaled breath condensate. Histamine
was detectable in the breath condensate of all of
the subjects and healthy, and its concentrations
were unchanged after AMP challenge (4.570.5 vs.
5.770.9 nM; P40.05, Fig. 3).
Cys-LTs were detectable in 12/13 asthmatic
patients and in all healthy subjects. We found a
significant increase in cys-LTs concentrations after
AMP challenge in asthmatics (from 31.776.9 to
56.279.7 pg/ml; Po0.02, Fig. 4), but no change in
healthy subjects from 27.274.6 to 30.374.7 pg/
ml; P¼ ns. There were no correlation between
histamine and cys-LT levels and age, FEV1 or PC20 in
each groups of subjects.
Discussion
In asthmatic patients we found a significant
increase in cys-LT concentrations in exhaled breath
condensate after AMP challenge and a non-signifi-
cant trend towards an increase after the MCh
challenge, whereas histamine levels remained
unaffected by either (Fig. 3). This suggests that
the AMP may cause bronchoconstriction in asthma
by releasing cys-LTs from airway mast cells.
Cys-LTs are potent constrictors in human
bronchi in vitro, being approximately 1000 times
more potent than histamine and this effect is
mediated via the activation of cys-LT receptors
on airway smooth muscle cells. In addition, airways
of asthmatics are may be usually more responsive
to cys-LTs than those of healthy subjects, although
the magnitude of the difference varies.8 Cys-LTs
are potent constrictors of both peripheral and
central airway smooth muscle. Previous studies
have found that the cys-LT release from blood
leukocytes is greater in asthmatics than in con-
trols,9 and high levels of LTE4 were found in the
urine of patients suffering from spontaneous
asthma attacks,10 exercise-induced bronchos-
pasm,11 nocturnal asthma exacerbations,12 and
mild and moderate asthma in comparison to
healthy subjects.
We did not find any change in cys-LT concentra-
tion in exhaled breath condensate after a MCh
challenge, and believe that the PC20 AMP (which
acts indirectly via the release of mediators from
primed mast cells) more closely reflects cell
activation in asthma patients than PC20 MCh, which
acts on airway smooth muscle cells (Fig. 4). Van
Den Berge et al.13 found that the PC20 AMP is more
closely associated with airway inflammation than
PC20 MCh, and Polosa et al.
14 found an association
between the number of eosinophilis in sputum and
PC20 AMP (but not PC20 MCh) in 12 subjects with
allergic rhinitis.
The fact that there was no change in
histamine levels after MCh or AMP challenge was
surprising. One probable explanation is that the
changes in histamine concentrations is not mani-
fest in detectable changes in exhaled breath
condensate.
An other possible explanation is that the inhaled
AMP releases cys-LTs from eosinophils rather than
mast cells. However, there is no evidence for
adenosine-induced activation of eosinophils
in vitro,15 so this is unlikely to account for the
increase in cys-LTs, but not in histamine.
Our results show that the cys-LTs are increased in
exhaled breath condensate after AMP challenge
indicating that the AMP acts indirectly by releasing
cys-LTs from primed mast cells. The detection of
cys-LT in exhaled breath condensate may be useful
as a means of detecting inflammatory cells in
asthma.
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Figure 3 Exhaled breath concentrations of histamine in
healthy control (Panel A) and patients with asthma (Panel
B) after adenosine 50-monophosphate challenge.
Figure 4 Exhaled breath concentrations of cys-LT in
healthy control (Panel A) and patients with asthma (Panel
B) after adenosine 50-monophosphate challenge.
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